Advanced Search

 

Study ID Status Title Patient Level Data
S3A40320 Completed An Open-label, Multicenter, Study of the Safety and Antiemetic Effect of 0.15 mg/kg Intravenous Ondansetron Hydrochloride Administered for Three Doses to Pediatric Cancer Patients Aged 6 Months to 48 Months Who Are Receiving Moderately to Highly Emetogenic Chemotherapy
S3A40323 Completed A Randomized, Double-blind, Placebo-controlled, Multi-center Study of Intravenous Ondansetron Hydrochloride 0.1 mg/kg for the Prevention of Postoperative Emesis in Pediatric Surgical Subjects Ages 1 Month to 24 Months Who Are Undergoing Routine Surgery Under General Anesthesia.
S3AA1002 Completed A Bioequivalence Study Comparing Three 8-mg Zofran® Tablets to a Single 24-mg Ondansetron Tablet
S3AA1003 Completed Dose-Response Effects of Ondansetron vs. Placebo on Morphine-Induced Nausea, Gastric Dysrhythmias and Plasma Vasopressin
S3AA3004 Completed A Randomized, Double-Blind Comparison of Oral Ondansetron and Intravenous Granisetron in the Prevention of Nausea and Vomiting Associated With Moderately-High Emetogenic Chemotherapy
S3AA3012 Completed A Randomized, Double-Blind Study of Oral Ondansetron, 8mg Twice Daily, 24mg Once Daily and 32mg Once Daily, in the Prevention of Nausea and Vomiting Associated With Cisplatin Chemotherapy
S3AA3013 Completed A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Single Dose Ondansetron 8mg and Single Dose Ondansetron 16mg for the Treatment of Opioid-Induced Nausea and Emesis in Subjects Experiencing Acute Pain
S3AA4001 Completed A Multicenter Study to Evaluate the Efficacy and Safety of a Repeat Dose of Ondansetron in Ambulatory Surgery Patients who do not Achieve Adequate Control of Postoperative Nausea and Vomiting Following Prophylaxis With Open-Label Intravenous Ondansetron
S3AA4002 Completed A Randomized, Double-Blind Comparison of Single-Dose Intravenous Ondansetron Versus Single-Dose Intravenous Granisetron in the Prevention of Nausea and Vomiting Associated with High-Dose Cisplatin Chemotherapy
S3AA4003 Completed A Stratified, Randomized, Double-Blind Comparison of Oral Ondansetron and Compazine® Spansules® in the Prevention of Nausea and Vomiting Associated With Moderately-Emetogenic Chemotherapy
S3AB3003 Completed A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Compare the Efficacy and Safety of Intravenous Doses of Ondansetron 4mg and 8mg in the Prevention of Postoperative Nausea and Emesis in Patients Undergoing Elective Major Abdominal Surgery
S3AB3004 Completed A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicentre Study to Compare the Efficacy and Safety of Intravenous Ondansetron 4mg and 8mg in the Prevention of Postoperative Nausea and Emesis In-Patients Undergoing Major Gynaecological Surgery
S3AB3005 Completed A Multicentre, Double-Blind, Double-Dummy, Randomised, Parallel-Group Study to Compare the Efficacy and Safety of Ondansetron 8mg bd Tablet and Ondansetron ZYDIS™ 8mg bd in the Control of Emesis and Nausea Induced by Cyclophosphamide-Containing Chemotherapy Treatment in Cancer Patients
S3AB3006 Completed A multicentre, double-blind, randomised, parallel group study to compare the efficacy and safety of two ondansetron regimens in the control of emesis and nausea induced by cancer chemotherapy in paediatric patients.
S3AB3008 Completed A multicentre, double-blind, double-dummy, parallel group study to compare the efficacy and safety of intravenous ondansetron 8mg plus intravenous dexamethasone 20mg with oral ondansetron 24mg od plus oral dexamethasone 12mg od in the control of acute emesis and nausea induced by cisplatin chemo ...
S3AC01 Completed A randomised, double-blind, placebo controlled, multicentre, parallel group study to evaluate the efficacy and safety of a single intravenous bolus dose of ondansetron in the prevention of postoperative nausea and emesis in patients having general anaesthesia and undergoing elective orthopaedic ...
S3AM23 Completed A Multicentre Double-blind Study to Compare the Efficacy and Safety of Ondansetron (GR 38032F) Administered Either as a Single Intravenous Dose or a Continuous Infusion in the Prophylaxis of Acute Nausea and Vomiting Induced by Cisplatin-containing Cancer Chemotherapy Regimens
S3AP31 Completed To Compare the Efficacy and Safety of Ondansetron with Dexamethasone in the Prophylaxis of Nausea and Vomiting Induced by Non-Platinum-Containing Cancer Chemotherapy Regimens
S3AP36 Completed A Multi-Centre Study to Assess the Clinical Efficacy and Safety of GR38032F in the Prophylaxis of Cisplatin-Induced Nausea and Vomiting
S3AP47 Completed A Pilot Study to Determine the Optimal Dose, Tolerance and Efficacy of Ondansetron (GR38032F) in the Prevention of Nausea and Vomiting Induced by Maintenance Therapy Used in Children with Acute Lymphoblastic Leukaemia
S3AP48 Completed A Pilot Study to Determine the Safety and Efficacy of Ondansetron (GR38032F) in the Prevention of Nausea and Vomiting Induced by Cancer Chemotherapy Regimens Containing Cisplatin, Carboplatin or Doxorubicin in Combination with either Cyclophosphamide or Ifosfamide in Children
S3AP54 Completed The pharmacokinetics of oral ondansetron (GR38032F) in elderly patients receiving cytotoxic chemotherapy or radiotherapy.
S3AT03 Completed A Randomised Double-Blind Multicentre Study to Compare the Clinical Efficacy and Safety of Ondansetron (GR38032F) and Metoclopramide in the Prophylaxis of Single Fraction Radiotherapy-Induced Nausea and Vomiting
S3AT07 Completed A Randomised, Double-Blind, Placebo Controlled Study Of The Efficacy And Safely Of Ondansetron (GR38032F) in The Prophylaxis Of Nausea And Vomiting Induced By The Combination Of Cyclophosphamide, Doxorubicin And Prednisolone With Vincristine (CHOP), VP16 Or VM26
S3AT17 Completed A Randomised Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Ondansetron Given Orally 8mg Three Times A Day in the Prophylaxis of Nausea and Vomiting Induced by the Combination of Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) in Women with Breast Cancer

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.